FingerMotion, Inc. shares surged over threefold on Friday, following the announcement of a modular artificial-intelligence data-center plan with BlueFlare Energy Solutions. The move boosted implied equity value by approximately $27.8 million.
The market priced an AI-infrastructure plan before contracts.
| Measure | Figure | Status |
|---|---|---|
| Lyken.AI ownership | 9.9% | Acquired |
| FNGR shares issued | 1,674,480 | Restricted |
| Cash paid | $0 | Equity-funded |
| B300 nodes | 128 | Nonbinding MOU |
The rally values execution that has not occurred. No site, power, customer or project-financing agreement is definitive. The Lyken customer memorandum is nonbinding. Equity consideration dilutes holders, while micro-cap liquidity can reverse quickly.
Illustrative milestone completion: strategy disclosed; four core contractual steps remain.
Sources: FingerMotion announcement and June 8-K; Aug. 28 filing summary; market data at 11:26:07 EDT. Implied prior market cap and value added are calculations from current market cap and the 261.7% price move. Not investment advice.
Reuters reported Nvidia paused some credit-support deals that exchanged financing help for cloud-revenue participation.
Nvidia said the broader compute-access model remains in place and continues to evolve.
| Metric | Value | Signal |
|---|---|---|
| Revenue | $1.93M | +412% YoY |
| Adjusted EBITDA | $0.59M | Positive |
| Net loss | −$430.4M | Mostly non-cash |
| Cash | $1.861B | Build-out buffer |
| Current note liabilities | $1.007B | Financing weight |
| Checkpoint | Why it matters |
|---|---|
| Financing terms | Determines deployment cost and equity dilution |
| GPU acceptance | Triggers capacity availability and revenue |
| Customer utilization | Turns reserved capacity into billed sales |
| Contract amendments | Tests whether Nvidia's pause reaches SharonAI |
| Cash burn | Measures runway during infrastructure ramp |
The stock move values implementation risk, not simply demand. SharonAI's SEC filing already says deployments need additional debt or equity financing and face phased acceptance tests.
Key question: can $8.8 billion of contracted value convert into revenue without costly new capital?
The ADSs opened at $102.34, traded as low as $98.80, then recovered part of the decline.
The monitoring board found a numerical overall-survival imbalance between arms and judged further continuation unlikely to change efficacy.
Stage II high-riskStage IIIctDNA-positivePost-surgery| Measure | Latest | Investor signal |
|---|---|---|
| Q2 revenue | €105.6m | Down 59.5% year over year |
| Q2 R&D expense | €551.0m | Heavy oncology investment continues |
| Q2 net loss | €820.8m | Up 112% year over year |
| 2026 revenue guide | €1.6–€1.9bn | Already reduced in August |
| 2026 adjusted R&D guide | €2.0–€2.3bn | Capital allocation becomes more important |
| Share repurchase authorization | Up to $1.0bn | Potential downside buffer, market-dependent |
Liquidity can absorb program failure, but repeated negative readouts would compress pipeline valuation.
| Consensus | Buy |
| Average target | $121.51 |
| Median target | $129.75 |
| Low / high | $76.14 / $145.26 |
| Coverage | 20 analysts |
Snapshot checked Aug. 28; ratings predate the trial termination.
Bull case: the stop saves future study spending and cash is redirected to stronger assets. Bear case: the survival signal weakens confidence in personalized mRNA oncology and raises scrutiny across partnered programs.
Reference points: $137.25 open, $147.77 high, $134.07 low, $137.86 latest.
Initial conversion equals roughly 3.1% of the June share base. The capped call is designed to offset dilution, but only up to its cap.
2032 maturityRule 144ASenior unsecured| Measure | Term | What it changes |
|---|---|---|
| Initial conversion | $210.58 | 47.5% premium to Thursday close |
| Capped-call ceiling | $392.6175 | Hedge protection to 175% premium |
| Expected net proceeds | $2.563bn | About 37% of June liquidity |
| Capped-call cost | $285m | About 11% of base net proceeds |
| Buyer option | Up to $400m | Could lift net proceeds near $2.96bn |
The financing replenishes flexibility after the settlement payment and ongoing research spending.
| Q2 revenue | $145m |
| Q2 EPS | −$1.97 |
| 2026 revenue plan | Up to +10% |
| Year-end cash guide | $4.7–$5.2bn |
| Analyst consensus | Hold |
| Average target | $106.63 |
Bull case: zero-coupon funding protects oncology momentum and the hedge limits dilution. Bear case: the stock remains above consensus value while cash burn and vaccine demand stay uncertain.
Roivant Sciences (NASDAQ: ROIV) · Market data at August 28, 2026, 09:39:23 EDT
| Previous close | $37.58 |
| Friday open | $37.01 |
| Early range | $36.49–$37.13 |
| 52-week range | $11.85–$37.95 |
| Average volume | 5.36M shares |
| Measure | LISRAYA 30mg | Placebo |
|---|---|---|
| Mean TIS, week 52 | 46.5 | 31.2 |
| Advantage | +15.3 points | — |
| Treatment discontinuation | 6% | 11% |
| Trial size | 241 adults; 52 weeks | |
Peak-sales estimate as a share of current equity value
7.6% · $2.0B / $26.42B
| Cash and securities, June 30 | $3.9B |
| Quarterly net loss | $290.6M |
| Quarterly R&D | $202.0M |
| Quarterly revenue | $1.4M |
| Share repurchases | $208.7M |
| Event | Status | Investor test |
|---|---|---|
| FDA approval | Completed Aug. 27 | Regulatory risk removed |
| Specialty-pharmacy launch | Immediate | Prescription conversion |
| Pricing disclosure | Pending | Gross-to-net revenue |
| Payer coverage | Developing | Launch velocity and access |
Pricing remains undisclosed. Payer restrictions could slow uptake in a small patient population. LISRAYA carries boxed warnings for serious infections, malignancy, major cardiovascular events and thrombosis.
Sources: FDA, Roivant, Reuters, Roivant quarterly results and Google Finance. Trial and financial data are company-reported unless noted.
Fiscal Q1 2027 results and premarket repricing
| Operating measure | Reported | Investor read-through |
|---|---|---|
| Adjusted EPS | $0.70 vs $0.58 consensus | Beat supports the rally |
| Q2 revenue midpoint | $486.5M vs $483M consensus | Modest upside to expectations |
| >$100K ACV customers | 1,800 vs 1,550 year ago | Enterprise cohort grew 16% |
| Non-GAAP operating margin | 16.2% | Positive adjusted leverage |
| GAAP operating margin | -5.0% | Profit-quality gap remains |
Current RPO grew six points faster than revenue. That expands near-term contracted visibility if deployments and renewals convert as planned.
A slower backlog conversion, rising AI infrastructure costs or stronger cloud competition could expose the gap between adjusted profit and the GAAP loss.
Sources: Elastic fiscal Q1 2027 release; FactSet estimates cited by Investors.com; StockAnalysis premarket quote. Market figures timestamped 28 Aug 2026, 08:03 EDT. Implied value change is an estimate, not a reported company figure.
FY2026 results and premarket reset · Market data at 07:14 EDT, August 28, 2026
ARR is a non-GAAP operating metric. IREN warns recognized revenue may be materially lower. Commissioning and customer acceptance govern conversion.
| US$ millions | Q4 | Q3 | Change |
|---|---|---|---|
| Total revenue | 137.2 | 144.8 | −5.2% |
| AI Cloud | 70.5 | 33.6 | +109.8% |
| Bitcoin mining | 66.7 | 111.2 | −40.0% |
| Adjusted EBITDA | 19.2 | 59.5 | −67.7% |
| Net loss | (684.0) | (247.8) | Wider |
Quarter-end cash and restricted cash: $7.62B.
Q4 operating cash flow: $1.81B, including a $1.72B increase in deferred revenue.
Deferred revenue supports cash flow before revenue recognition. It also creates delivery obligations.
The market is weighing a fast mix shift against its accounting cost. AI Cloud more than doubled sequentially, but adjusted EBITDA fell 68% and the quarter carried a $450.4M mining-hardware impairment.
The key question is no longer demand alone. It is how quickly contracted ARR becomes recognized revenue without further impairments, delays or financing strain.
52-week range
$25.31–$76.87
Short interest
30.61% of float
Three-month return
−36.21%
One-year return
+53.06%
| 2026 IT capacity target | 0.3 GW |
| 2027 IT capacity target | 0.8 GW |
| Horizon 1 | Accepted by Microsoft |
| Recent contract economics | >$20M revenue/MW |
| Claimed payback | ~2 years |
Commissioning delaysCustomer concentrationGPU supplyHardware obsolescenceDebt costBitcoin exposure
The $4B contracted ARR figure is not recognized revenue. Timing, utilization, uptime and customer acceptance remain decisive.
Sources: IREN FY2026 results; MarketWatch quote and ownership data; Investors.com market report. Financial figures in U.S. dollars. Calculations may differ due to rounding.
NFL distribution is secured; unit economics remain the real contest.
Volume and users expanded, but game outcomes and promotions compressed monetization.
The renewal preserved distribution but did not reverse the de-rating.
| Signal | DraftKings | FanDuel parent Flutter | What matters |
|---|---|---|---|
| Q2 revenue | $1.443B, −5% | $4.326B, +3% groupwide | Growth quality diverged |
| Activity | $13.1B sports volume, +15% | FanDuel retains NFL sportsbook status | Access is broad; conversion decides value |
| Profit signal | FY26 EBITDA guide $700M–$900M | Q2 adjusted EBITDA $508M, −45% | Promotions and taxes pressure margins |
| Market close | $24.22, −2.3% | $95.01, −3.1% | Investors remain cautious |
DraftKings and FanDuel retain promotion, real-time statistics, event presence and NFL digital integrations. DraftKings also keeps daily fantasy status. Fanatics joins as a third sportsbook partner and gains online-casino marketing rights.
Positive: payer retention and cross-sell. Negative: customer-friendly results or higher acquisition costs.
Nvidia's forecast lifted Intel 4.36%; the close remains below Intel's recent $95 share-sale price.
| Company | Close | Move | Volume | Trailing P/E |
|---|---|---|---|---|
| Intel | $92.09 | +4.36% | 100.56M | N/M |
| Nvidia | $227.98 | +8.72% | 298.91M | 28.6× |
| AMD | $476.67 | −0.86% | 16.44M | 122.5× |
| Micron | $935.39 | −0.36% | 28.84M | 21.2× |
The split tape matters: Thursday rewarded Intel's AI exposure, but the whole semiconductor group did not rally.
| Q2 revenue | $16.1B | +25% |
| GAAP gross margin | 40.4% | +12.9 pts |
| GAAP operating margin | 11.1% | +35.8 pts |
| Non-GAAP net income | $2.2B | vs. loss |
| GAAP net result | −$11.0B | loss |
Revenue and margins rose sharply, but the GAAP loss kept earnings quality in focus.
Intel sold 210.5 million shares at $95, creating a clear dilution and execution benchmark.
Nvidia's forecast lifted Intel, yet no new Intel design win was announced.
Intel's 4.36% gain says the market sees value in its exposure to expanding AI budgets. The harder test is conversion: foundry utilization, server share, margin durability and cash generation must justify both a $470 billion valuation and the new capital raised at $95.
Cost controls and a 15% workforce reduction lifted the earnings outlook. Revenue grew just 0.8%, leaving shares almost unchanged after hours.
Q2 FY2027Reported Aug. 27, 2026The margin expansion is the dominant signal. Customer and recurring-revenue growth remain modest.
| Metric | New | Prior | Midpoint change |
|---|---|---|---|
| FY revenue | $491.5M–$496.5M | $488.5M–$496.5M | +0.3% |
| FY adj. EPS | $1.33–$1.37 | $1.27–$1.32 | +4.2% |
| Q3 revenue | $123M–$125M | — | New |
| Q3 adj. margin | 26.5%–27.5% | — | New |
Bull case: The restructuring protects cash generation and supports a higher EPS range. Q2 beat revenue guidance, and free cash flow improved.
Bear case: ARR grew only 0.4% and retention stayed below 100%. The stock already trades above the average analyst target.
Watch next: Q3 revenue of $123M–$125M, adjusted margin of 26.5%–27.5%, retention and the pace of restructuring charges.
The fundamentals beat estimates, but not elevated AI expectations. Q3 revenue guidance exceeded consensus by about 4%, while the non-GAAP gross-margin midpoint falls 90 basis points sequentially.
| Metric | Q2 FY26 | Q2 FY27 | YoY |
|---|---|---|---|
| Revenue | $2.006B | $2.739B | +36.5% |
| GAAP operating income | $290.1M | $459.7M | +58.5% |
| GAAP gross margin | 50.4% | 53.1% | +270 bp |
| Operating cash flow | — | $605.5M | — |
| Metric | Guide midpoint | Consensus | Premium |
|---|---|---|---|
| Revenue | $3.15B | $3.03B | +4.0% |
| Adjusted EPS | $1.10 | $1.07 | +2.8% |
| Non-GAAP gross margin | 58.0% | — | −90 bp QoQ |
Revenue midpoint implies roughly 15% sequential growth.
Watch: custom-silicon ramps, optical demand, customer concentration, supply, gross-margin conversion and cash returns.
| Operating ARR | $1.0B |
| Contracted 2026 ARR | $4.0B |
| 2026 IT capacity | ~0.3GW |
| 2027 IT capacity target | ~0.8GW |
| Recent revenue / MW | >$20M |
| Customer prepayments | 45–55% GPU capex |
| Metric | FY25 | FY26 | Change |
|---|---|---|---|
| Total revenue | $501.0M | $707.0M | +41.1% |
| AI Cloud revenue | $16.4M | $128.8M | +685% |
| Adjusted EBITDA | $269.7M | $245.7M | -8.9% |
| Net income/(loss) | $86.9M | -$702.6M | NM |
| Regular close | $40.53 |
| After-hours | $38.11 |
| Implied value change | ~-$865M |
| 52-week range | $22.63–$76.87 |
| Ratings | 7 Buy / 2 Hold / 1 Sell |
| Average target | $77.44 |
Watch: quarterly adjusted EBITDA fell 67.7% sequentially as staffing and platform costs arrived before the revenue ramp. Deferred revenue drove $1.722 billion of quarterly operating cash flow.
Market snapshot: August 27, 2026, 17:30 EDT · Quarter ended July 31
Bar lengths are normalized within each comparison, not a common scale.
| Metric | Current | Investor signal |
|---|---|---|
| Q3 subscription revenue | ~$2.515B | Broadly in line |
| FY subscription revenue | $9.94–$9.95B | Tiny midpoint raise |
| New buyback authorization | $4.0B | ~9% of AH value |
| After-hours value loss | ~$3.3B | 7.02% move |
| Consensus | Outperform |
| Analysts | 41 |
| Average target | $188.21 |
| Median target | $202.00 |
| Target range | $92–$275 |
| Upside to average | 4.6% |
Watch enterprise IT budgets, large-deal timing, AI pricing, Financials adoption and acquisition speculation. Extended-hours liquidity can amplify the move.
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | $427.3M | $309.9M | +38% |
| Subscription ARR margin | 14.0% | 9.4% | +4.6 pp |
| Non-GAAP gross margin | 81.0% | 81.6% | −0.6 pp |
| Free cash flow | $65.7M | $57.5M | +14% |
| FCF margin | 15% | 19% | −4 pp |
| Metric | Prior range | New range | Midpoint lift |
|---|---|---|---|
| Revenue | $1.638B–$1.648B | $1.685B–$1.693B | +$46M |
| Subscription ARR | $1.854B–$1.862B | $1.880B–$1.885B | +$24.5M |
| Free cash flow | $293M–$303M | $323M–$333M | +$30M |
| Adjusted EPS | $0.25–$0.35 | $0.47–$0.53 | +$0.20 |
3,084 large customers+23% YoY$1.75B liquidity
Extended-hours liquidity can distort price discovery. Rubrik remains GAAP-loss-making. Non-GAAP gross margin slipped 0.6 point, free-cash-flow margin fell four points, and a record-high setup leaves little room for execution misses.
Sources: Rubrik/Business Wire results, Rubrik prior guidance, Public after-hours data, WSJ market data and Yahoo Finance analyst data. Figures are company-reported unless otherwise stated.
| Registry field | Before | Aug. 26 update |
|---|---|---|
| Site footprint | Original site set | Baylor College of Medicine added |
| Recruitment | Not yet recruiting | Unchanged |
| Enrollment | 20 | Unchanged |
| Estimated start | Jul. 31, 2026 | Aug. 31, 2026 |
| Primary/final completion | Mar. 31, 2027 | Aug. 31, 2027 |
| Path | Confirmation signal | What would challenge it |
|---|---|---|
| Bull | Recruitment begins; FDA pathway gains clarity; short covering persists | Further trial slippage or weak dosing demand |
| Base | Registry edit stays procedural; shares consolidate into the next data event | Company-specific disclosure changes the evidence set |
| Bear | Delay and safety concerns dominate; squeeze fades | Fast activation plus credible label-expansion progress |
| Metric | Latest | Signal |
|---|---|---|
| Q1 FY2027 bookings | $1.39B | −3% year on year; slightly above guidance |
| Recurrent consumer spending | 84% of bookings | −1% year on year |
| FY2026 bookings | $6.72B | Baseline before GTA VI launch year |
| GTA V installed base | >230M units | Proof of franchise durability |
| GTA VI pre-orders | “Unprecedented” | Management description; not yet recognized sales |
Search attention and the showcase are strong. The stock still fell 2.12%, suggesting investors want execution evidence, not another anticipation cycle.
At $228.50, the market discounts roughly 30% upside to the analyst target. That spread also embeds delay, launch-quality and mobile-performance risk.
The common stock added roughly $5.2 billion of quoted value. The bitcoin reserve gained about $1.9 billion at the same snapshot.
Before debt, preferred equity, tax and other claims.
| Measure | Reading | Why it matters |
|---|---|---|
| BTC acquisition cost | $63.36B / $75,385 each | Current token price sits 6.6% higher |
| USD Reserve | $5.10B | Supports dividends and interest |
| USD Cash | $1.59B | Flexible treasury deployment |
| Q2 long-term debt | $6.7B | Down 18% in the quarter |
| Q2 preferred equity | $14.4B | Senior claim to common stock |
| Q2 software revenue | $122.4M | Up 6.9% year over year |
| Action, Aug. 17–23 | Amount | Investor interpretation |
|---|---|---|
| MSTR shares sold | 18.26M | Common-stock dilution |
| Net proceeds | $2.0065B | About $109.88 per share |
| STRC repurchase | $136.4M | Reduces preferred claim |
| USD Reserve increase | $300M | Extends obligation coverage |
| Bitcoin traded | None | 840,447 BTC unchanged |
MSTR’s daily gain materially exceeded bitcoin’s. That leverage can reverse. Common issuance, preferred dividends, debt service, tax changes, regulation and contraction of the equity multiple can outweigh a stable token price.
Primary data: Strategy Aug. 24 Form 8-K and Q2 2026 results. Market data timestamped above.
Salesforce market data at 10:28 EDT; operating metrics released Aug. 26.
| Company | Price | Move |
|---|---|---|
| ServiceNow (NOW) | $137.16 | +9.03% |
| Salesforce (CRM) | $248.29 | +20.75% |
| Workday (WDAY) | $197.39 | +3.48% |
| Oracle (ORCL) | $150.84 | +1.32% |
NOW at 10:37 EDT; peer prices at about 10:28 EDT on Aug. 27, 2026.
2:40 p.m. EDT today
ServiceNow CFO Gina Mastantuono speaks at Deutsche Bank's technology conference.
Next quarter
Watch whether cRPO holds near 20% constant-currency growth and AI ACV converts into subscriptions.
Risk
The rally is a peer read-through. Average target upside is now only 3.7%.
The U.S. search phrase “now stock” also points to ServiceNow's expanded Tech Mahindra partnership. It was announced Aug. 20, not today. Tech Mahindra says its ServiceNow deployment handles more than 100,000 monthly cases across 90 countries, supports 150,000 employees and has optimized about 25% of first-level support work.
The AI-memory read-through remains strong. Price action says investors still want Micron-specific proof on HBM volume, pricing and margins.
August 27 value is intraday at 09:39 EDT; earlier values are official closes. The stock opened at $967.01 before fading.
| Metric | Current / latest | Comparison | Investor reading |
|---|---|---|---|
| Fiscal Q3 revenue | $41.46B | $23.86B prior quarter | +73.8% sequential |
| Operating cash flow | $25.39B | $11.90B prior quarter | Cash conversion strengthened |
| Adjusted free cash flow | $18.3B | $7.1B capex | Funds expansion internally |
| Adjusted gross margin | 84.9% | 74.9% prior quarter | Exceptional, hard to sustain |
| Forward P/E | 6.5× | 21.2× trailing | Large earnings-cycle assumption |
| Net cash | $23.75B | $21.03 per share | Balance-sheet cushion |
HBM is stacked memory placed beside AI accelerators. Higher accelerator shipments increase the addressable memory content, but Micron’s realized revenue still depends on qualification, allocation, pricing and yield.
| Reference | Target / value | Upside from $943.46 | Implied FY2027 P/E |
|---|---|---|---|
| Current price | $943.46 | — | 6.1× |
| BMO / Mizuho | $1,300 | 37.8% | 8.4× |
| Analyst average | $1,515 | 60.6% | 9.8× |
| Analyst low | $361 | −61.7% | 2.3× |
| Analyst high | $2,200 | +133.2% | 14.2× |
